Renal transplant remains the treatment of choice for end-stage renal disease.1 Unfortunately, long-term graft failure rates are unsatisfactory. One potential therapy is fingolimod (FTY720), a new immunomodulator that reduces lymphocyte recirculation from lymphoid tissue to blood and peripheral tissues.2 We describe a renal transplant recipient in a phase IIIb clinical trial of fingolimod who developed cystoid macular edema (CME).
Georges Saab, Arghavan Almony, Kevin J. Blinder, Rebecca Schuessler, Daniel C. Brennan. Reversible Cystoid Macular Edema Secondary to Fingolimod in a Renal Transplant Recipient. Arch Ophthalmol. 2008;126(1):140–141. doi:10.1001/archophthalmol.2007.23